John .... as the issue in Europe is only that there's insufficient trial data in that age group (although it appears the jab is perfectly safe and effective via other evidence) .... by the time we're jabbed to the point of unloading surplus orders, that evidence will be there in bundles and our neighbours will have upgraded their advice.
K
I hope so ,as there has been a suggestion that the Swiss rejection is more about their domestic Pharma business is close to producing its own vaccine. I do get a sense of political manoeuvring, in that if you discount one source of vaccine you can use limited supplies of the approved vaccine to justify late vaccination programme roll out.
The UK trials about to start, regarding mixing different brand vaccines administered to an individual to increase effectiveness to counter new variants etc may prove important as it works for mixed vaccines with Ebola etc.
regards
